NO325631B1 - Fremgangsmate for bestemmelse av infeksjoner pa proteser - Google Patents
Fremgangsmate for bestemmelse av infeksjoner pa proteser Download PDFInfo
- Publication number
- NO325631B1 NO325631B1 NO20003919A NO20003919A NO325631B1 NO 325631 B1 NO325631 B1 NO 325631B1 NO 20003919 A NO20003919 A NO 20003919A NO 20003919 A NO20003919 A NO 20003919A NO 325631 B1 NO325631 B1 NO 325631B1
- Authority
- NO
- Norway
- Prior art keywords
- polysaccharide
- supernatant
- staphylococcus
- centrifugation
- suspending
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title claims description 31
- 238000000034 method Methods 0.000 title claims description 25
- 229920001282 polysaccharide Polymers 0.000 claims description 32
- 239000005017 polysaccharide Substances 0.000 claims description 32
- 241000191940 Staphylococcus Species 0.000 claims description 22
- 239000006228 supernatant Substances 0.000 claims description 15
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 8
- 210000003097 mucus Anatomy 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000013060 biological fluid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 230000000951 immunodiffusion Effects 0.000 claims description 2
- 238000000760 immunoelectrophoresis Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 6
- 238000011033 desalting Methods 0.000 claims 2
- 210000002615 epidermis Anatomy 0.000 claims 1
- 150000004804 polysaccharides Chemical class 0.000 description 26
- 230000002792 vascular Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000012620 biological material Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010056559 Graft infection Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000006156 Mannitol salt agar Substances 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000002181 esophagogastroduodenoscopy Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Dental Preparations (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98MI000197A IT1298539B1 (it) | 1998-02-03 | 1998-02-03 | Metodo per la determinazione di infezioni da protesi |
| PCT/EP1999/000618 WO1999040440A1 (en) | 1998-02-03 | 1999-02-01 | Method for the determination of prosthetic infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20003919D0 NO20003919D0 (no) | 2000-08-02 |
| NO20003919L NO20003919L (no) | 2000-09-29 |
| NO325631B1 true NO325631B1 (no) | 2008-06-30 |
Family
ID=11378802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20003919A NO325631B1 (no) | 1998-02-03 | 2000-08-02 | Fremgangsmate for bestemmelse av infeksjoner pa proteser |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7807395B2 (de) |
| EP (1) | EP1053474B1 (de) |
| JP (2) | JP2002502978A (de) |
| AU (1) | AU2520299A (de) |
| CA (1) | CA2319575C (de) |
| DE (1) | DE69919512T2 (de) |
| DK (1) | DK1053474T3 (de) |
| ES (1) | ES2228007T3 (de) |
| IL (1) | IL137439A0 (de) |
| IT (1) | IT1298539B1 (de) |
| NO (1) | NO325631B1 (de) |
| WO (1) | WO1999040440A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7252828B2 (en) | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
| AU2003290867A1 (en) | 2002-11-12 | 2004-06-03 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
| ES2648046T3 (es) | 2002-11-12 | 2017-12-28 | The Brigham And Women's Hospital, Inc. | Vacuna de polisacárido para infecciones estafilocócicas |
| EP2455401B1 (de) | 2004-04-21 | 2018-01-24 | The Brigham and Women's Hospital, Inc. | Poly-n-acetylglucosamin (pnag/dpnag)-bindenden antikörper |
| CN105085349B (zh) | 2008-07-21 | 2018-02-09 | 布赖汉姆妇女医院 | 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物 |
| RU2518249C1 (ru) * | 2012-10-16 | 2014-06-10 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ определения неспецифической устойчивости патогенных микроогранизмов к антибиотикам на основании измерения каталитической активности фосфодиэстераз, расщепляющих циклический дигуанозинмонофосфат |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI40107C (fi) * | 1961-05-15 | 1968-10-10 | Parke Davis & Co | Menetelmä uuden stafylokokkiantigeenin valmistamiseksi |
| US5055455A (en) * | 1988-09-28 | 1991-10-08 | Brigham And Women's Hospital | Capsular polysaccharide adhesin antigen, preparation, purification and use |
| WO1991003572A1 (en) * | 1989-09-08 | 1991-03-21 | Wisconsin Alumni Research Foundation | Test for the detection of staphylococcal fibronectin-receptor antibodies |
| WO1993010847A1 (en) * | 1991-12-06 | 1993-06-10 | North Shore University Hospital Research Corporation | Method of reducing medical device related infections |
| ATE209659T1 (de) * | 1994-09-21 | 2001-12-15 | Jackson H M Found Military Med | Breit-reaktive opsonische antikörper, die mit gemeinsamen staphylococcus-antigenen reagieren |
-
1998
- 1998-02-03 IT IT98MI000197A patent/IT1298539B1/it active IP Right Grant
-
1999
- 1999-02-01 JP JP2000530802A patent/JP2002502978A/ja active Pending
- 1999-02-01 IL IL13743999A patent/IL137439A0/xx not_active IP Right Cessation
- 1999-02-01 EP EP99904832A patent/EP1053474B1/de not_active Expired - Lifetime
- 1999-02-01 DE DE69919512T patent/DE69919512T2/de not_active Expired - Lifetime
- 1999-02-01 DK DK99904832T patent/DK1053474T3/da active
- 1999-02-01 ES ES99904832T patent/ES2228007T3/es not_active Expired - Lifetime
- 1999-02-01 WO PCT/EP1999/000618 patent/WO1999040440A1/en active IP Right Grant
- 1999-02-01 AU AU25202/99A patent/AU2520299A/en not_active Abandoned
- 1999-02-01 CA CA2319575A patent/CA2319575C/en not_active Expired - Fee Related
-
2000
- 2000-08-02 NO NO20003919A patent/NO325631B1/no not_active IP Right Cessation
-
2002
- 2002-05-01 US US10/135,827 patent/US7807395B2/en not_active Expired - Fee Related
-
2010
- 2010-01-29 JP JP2010018353A patent/JP4934729B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7807395B2 (en) | 2010-10-05 |
| US20020197280A1 (en) | 2002-12-26 |
| AU2520299A (en) | 1999-08-23 |
| CA2319575C (en) | 2011-09-13 |
| EP1053474A1 (de) | 2000-11-22 |
| ES2228007T3 (es) | 2005-04-01 |
| JP2002502978A (ja) | 2002-01-29 |
| NO20003919L (no) | 2000-09-29 |
| EP1053474B1 (de) | 2004-08-18 |
| DE69919512T2 (de) | 2005-09-29 |
| JP4934729B2 (ja) | 2012-05-16 |
| ITMI980197A1 (it) | 1999-08-03 |
| IT1298539B1 (it) | 2000-01-12 |
| IL137439A0 (en) | 2001-07-24 |
| WO1999040440A1 (en) | 1999-08-12 |
| NO20003919D0 (no) | 2000-08-02 |
| CA2319575A1 (en) | 1999-08-12 |
| JP2010145416A (ja) | 2010-07-01 |
| DK1053474T3 (da) | 2004-12-20 |
| DE69919512D1 (de) | 2004-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Epstein et al. | Effects of specific antibodies on the interaction between the fungus Candida albicans and human oral mucosa | |
| CN101395476A (zh) | 多重耐药葡萄球菌的免疫色谱检测方法和诊断试剂盒 | |
| Colomer-Winter et al. | Biofilm assays on fibrinogen-coated silicone catheters and 96-well polystyrene plates | |
| JP4934729B2 (ja) | プロテーゼ感染の決定のための方法 | |
| Rafiq et al. | Serological detection of Gram-positive bacterial infection around prostheses | |
| Almeida et al. | Capsulelike surface material of Mycoplasma dispar induced by in vitro growth in culture with bovine cells is antigenically related to similar structures expressed in vivo | |
| Boraker et al. | BrucELISA: an enzyme-antibody immunoassay for detection of Brucella abortus antibodies in milk: correlation with the Brucella ring test and with shedding of viable organisms | |
| EP3608672B1 (de) | Auf rohem nativem hapten basierender indirekter elisa-test und lyophilisierte kontrollen zur bestätigungsdiagnose von rinder-brucellose in blutserum und milch durch tier und tank | |
| Nath et al. | A community study on the aetiology of childhood diarrhoea with special reference to Campylobacter jejuni in a semiurban slum of Varanasi, India | |
| Petersen et al. | Francisella and Brucella | |
| US8426139B2 (en) | Polypeptides for identifying in vitro and preventing staphyloccocal infections on joint prostheses and other implanted foreign materials | |
| Strzelec-Nowak et al. | Investigation of the actual causes of hip joint implant loosening classified as aseptic–analysis of microbiological culture results and levels of inflammatory markers | |
| US20170045532A1 (en) | Materials and methods for diagnosis of peri-implant bone and joint infections using prophenoloxidase pathway | |
| JPS60224068A (ja) | 日和見感染における病原菌の判定方法 | |
| EP2205735B1 (de) | Immunologische testverfahren auf das vorliegen von bakterien unter verwendung von mit einem spezifischen verfahren gewonnenen antikörpern | |
| Welch et al. | Simplified procedure for tissue culture in routine detection of cytotoxins. | |
| KR19990063833A (ko) | 헬리코박터 파이로리 단백질 | |
| Gudding | Measurement of Staphylococcus Aureus Nuclease and Antinucleases: Applicability for The Assessment of Mastitic Milk | |
| Taylor et al. | Infection of total hip prostheses by Peptococcus magnus: an immunofluorescence and ELISA study of two cases. | |
| Mohammed et al. | Development and evaluation of an enzyme-linked immunosorbent assay for endotoxin in milk | |
| Thomas et al. | Antibody response to Staphylococcus aureus surface proteins in rabbits with persistent osteomyelitis after treatment with demineralized bone implants | |
| RU1816320C (ru) | Способ определени обсемененности желчи энтеробактери ми | |
| Braconier et al. | Indirect immunofluorescence as a diagnostic tool in a prosthetic heart valve endocarditis due to actinobacillus actinomycetemcomitans and staphylococcus epidermidis | |
| Parija et al. | Staphylococci adherence test for serodiagnosis of amoebiasis | |
| SU1751196A1 (ru) | Штамм бактерий YeRSINIa еNтеRосоLIтIса серовара 03, используемый в качестве антигена дл серодиагностики иерсиниоза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |